[Summary] Committed to continuous innovation in biotechnology, providing product
Xiamen Amoytop Biotech Co., Ltd. was established in 1996, specializing in biomedical research and industrialization centered on gene engineering technology. It is a "National Innovative Enterprise" and "National Key High-tech Enterprise" integrating research, development, and production. Currently, its marketed products include two national Class 1 new biological products - Pegbray® and Peijin® - and three former national Class 2 new biological products (Telil® , Telijin® , and Telcon®). Injectable finished products are sold in more than 10 countries, including China, Brazil, India, and Russia. Amoytop Biotech, focusing on the technical needs related to the treatment of major diseases in China, is committed to continuous innovation in the biotechnology field. It has built a professional innovative talent team, which was selected as the "National Key Field Innovation Team" by the Ministry of Science and Technology. It has established an innovative biomedical industrialization system from basic research, pilot research, clinical research to industrialization. It undertakes national major new drug innovation projects and international science and technology cooperation projects, and has multiple invention patents authorized in more than 30 countries and regions, including China, Europe, the United States, and Japan. Four long-acting national Class 1 new biological products with independent intellectual property rights have entered the clinical research stage, and multiple original biotechnology products are undergoing preclinical research. In accordance with international biopharmaceutical industry guidelines and EU and FDA standards, Amoytop Biotech has built a multi-product production base for recombinant protein drugs. Based on the concepts of drug lifecycle, risk management, and quality by design, it has established a comprehensive quality management system. It has obtained laboratory accreditation from the China National Accreditation Service for Conformity Assessment (CNAS) and has participated in more than 20 domestic and international product standard preparations and collaborative calibrations. In the future, Amoytop Biotech will continue to maintain a high level of scientific research investment, actively meet clinical treatment needs, focus on exploring immunotherapy solutions, and strive to develop into a leading international biotechnology enterprise.
What does Xiamen Amoytop Biotech Co., Ltd. require? Who is Amoytop Biotech hiring? Amoytop Biotech recruitment: 销售类占比最多占61.6%，其次是医疗卫生/美容保健类占59.2%. What education can get in at Amoytop Biotech? 大专占比最多占44.5%，其次是本科占42.3%. High education required at Amoytop Biotech? 硕士占6.1%，博士占2.1%. Work experience required at Amoytop Biotech? 1-3年占比最多占56.6%，其次是不限占19.1%. Where are the job locations at Amoytop Biotech? 厦门占比最多占18%，其次是上海占5.7%. Based on job postings from the past year, for reference only.
Provided by
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows
Jobui does not provide an APP. Please follow our WeChat official account.
